Answers are grounded in this paper and cite their sources.
Background Immune checkpoint inhibitors (ICIs) improved outcomes in advanced non‐small cell lung cancer (NSCLC), yet reliable blood‐based biomarkers remain lacking. Methods and material DNA Methylation‐based immune cell deconvolution (methylation cytometry) was used to retrospectively analyze blood samples drawn before initiation of ICI from patients with advanced NSCLC. Patients were prospectively enrolled in an observational biobanking program and treated with ICIs. Treatment response was assessed by centralized radiological review. Associations between methylation‐derived immune profiles and objective response (OR), progression‐free survival (PFS) and overall survival (OS) were evaluated using multivariable logistic and Cox regression models. Results A total of 75 patients with NSCLC were included in the cohort (median age 66 years, IQR 61–72; 47% female). OR occurred in 39% of evaluable patients ‐ no methylation‐derived immune cell profile was independently associated with OR. However, higher proportions of CD4+ T cells, memory and naïve CD4+ T cells, naïve CD8+ T cells and total lymphocytes were independently associated with prolonged PFS and OS, while elevated neutrophil fractions predicted inferior survival. Conclusions In our cohort of advanced NSCLC patients methylation cytometry showed potentially prognostic systemic immune features with clinical outcome parameter.
No takes yet. Share an insight, caveat, or question.
Kleinberger et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: